FDA Approves Asciminib for Patients With Chronic Myeloid Leukemia

The FDA has granted accelerated approval to asciminib (Scemblix®, Novartis AG) for patients with Philadelphia chromosome–positive (Ph-positive) chronic myeloid leukemia (CML) who have disease in chronic phase and were previously treated with two or more tyrosine kinase inhibitors and for those whose disease is in chronic phase with the T315I mutation."Patients with CML in chronic phase CML resistant or intolerant to ≥2 tyrosine kinase inhibitors (TKIs) are at high risk of experiencing poor outco...
Continue reading

Dasatinib Improves Outcomes in Patients With Chronic Myeloid Leukemia and High BMI

According to a subgroup analysis of a phase 3 study, dasatinib produces significantly faster and more durable responses compared with imatinib in patients with chronic phase chronic myeloid leukemia (CML) and a high body mass index (BMI). Previous studies have reported that patients with a high BMI, defined as over 25 kg/m2, are at an increased risk of not only developing CML but also of experiencing poorer outcomes when treated with first-line tyrosine kinase inhibitors (TKIs) such as imatinib....
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.